Kornimate/medical-research-clean huggingface dataset:
mnk6106 for liver disease (hepatic cirrhosis) that in the past has affected the brain (hepatic encephalopathy)

Conditions: Hepatic Cirrhosis; Hepatic Encephalopathy (HE)

Summary: the main reason for this study is to see how the study drug interacts with the body. it will compare different doses of the study drug with a drug already in use. participants will be adults with liver disease that has affected the brain in the past.


Eligibility criteria:
key inclusion criteria: a potential participant may only be included if (at screening), he/she: 1. understands the study and has signed informed consent 2. is an adult, not pregnant or lactating 3. has cirrhosis of the liver 4. has had 1 instance of he within 12 months 5. has hyperammonaemia defined as ≥37 μmol/l at screening key exclusion criteria: a potential participant will be excluded if (at screening), he/she: 1. has contraindicated allergies 2. expects liver transplant within 1 month 3. has had a liver shunt within the last 3 months 4. has inadequate kidney, gastrointestinal, or cardiac function 5. has cancer, infection, lab abnormalities, or any other condition that, per protocol or in the opinion of the investigator might compromise: 1. the safety and well-being of the participant or potential offspring 2. the safety of study staff 3. the analysis of results
toripalimab combined with gemcitabine/5--fluoropyrimidine for advanced cholangiocarcinoma

Conditions: Advanced Cholangiocarcinoma

Summary: the study is a phase ii clinical trial of single arm. the purpose is to evaluate the safety and efficacy of anti-pd-1 antibody toripalimab combined with chemotherapy(gemcitabine+5-fluorine pyrimidine) in unresectable advanced cholangiocarcinoma patients.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed cholangiocarcinoma * stage iv disease,no system therapy for advanced disease * one or more lesions that can be measured by imaging assessment * 18 to 70 years of age and life expectancy exceeds 3 months * adequate specimens for detection of pd-1/pd-l1 and mmr * karnofsky performance status(kps) score ≥70% * routine blood routine, liver and kidney function and electrocardiogram were basically normal without contraindication of chemotherapy. exclusion criteria: * dual cancers other than cholangiocarcinoma * metastasis of central nervous system * unreleased biliary obstruction * acute infections requiring treatment * non-infectious pneumonia requires glucocorticoid therapy, active autoimmune diseases, or systemic immunosuppressive therapy.
registry of non-primary angioplasty at hospitals without surgery on-site

Conditions: Coronary Artery Disease; Heart Attack; Angina

Summary: this is a simple registry of patients undergoing pci at hospitals without surgery on-site who were participants in the cport-e project. the aim of the registry is simple data collection and reporting to respective state departments of health. the registry population consists of patients undergoing diagnostic cardiac catheterization for suspected cad at hospitals without sos and who require pci.


Eligibility criteria:
inclusion criteria: patient inclusion criteria are: pre-catheterization 1. must be undergoing diagnostic cardiac catheterization for suspected cad 2. be at least 18 years of age 3. must not be pregnant (negative pregnancy test) or must not be of childbearing potential 4. must be able to give informed consent. post-catheterization 5. coronary artery disease judged to be clinically and angiographically significant 6. ability to perform pci with equipment available at the local site (see below) 7. procedure risk judged to be not high (see below) exclusion criteria: patient exclusion criteria are: pre-catheterization 1. inability to give informed consent 2. st-segment elevation myocardial infarction 3. pregnancy post-catheterization 4. high likelihood of requiring a device not available at the hospitals without sos (see below) 5. no need for pci 6. need for coronary artery bypass surgery 7. high procedural risk (see below)
evaluation of bilirubin estimates in newborns from smartphone digital images in a nepali population

Conditions: Jaundice, Neonatal

Summary: this cross-sectional study evaluates the accuracy of a novel smartphone application that estimates bilirubin levels in newborns at dhulikhel hospital, kathmandu nepal.

this cross-sectional study evaluates the accuracy of a novel smartphone application that estimates bilirubin levels in 200 newborns at dhulikhel hospital, kathmandu nepal. the picterus calibration card was placed on the chest of the newborn with the hole in the card placed over the infant's sternum. a validated smartphone with picterus jp was used to collect digital images.

Eligibility criteria:
inclusion criteria: * infants born with gestational age ≥35 weeks * birth weight ≥ 1750g * age 1 - ≤14 days * infants that will have a blood sample draw exclusion criteria: * infants in the need for respiratory support * infants with conditions that could compromise skin circulation, as sepsis, heart failure * infants that have received phototherapy
the use of drospirenone/estetrol in random start rapid endometrial preparation

Conditions: Endometrial Polyp; Endometrial Diseases

Summary: the presence of a thin endometrium plays an important role in enabling the best conditions for hysteroscopic surgery. recently, for this purpose, many studies have evaluated the effect of preoperative administration of a variety of drugs. we explored the efficacy of random started 14-day administration of drospirenone/estetrol, in rapid preparation of endometrium for hysteroscopic polypectomy.


Eligibility criteria:
inclusion criteria: * patients with endometrial polyps. exclusion criteria: * patients with other endometrial pathologies.

Keywords: hysteroscopy endometrial preparation
transcranial magnetic stimulation for methamphetamine use disorder in plwh

Conditions: Methamphetamine Use Disorders; HIV

Summary: the purpose of this study is to learn more about how accelerated theta burst stimulation affects methamphetamine craving and brain activity. theta burst stimulation is a unique transcranial magnetic stimulation (tms) paradigm that is efficient and potent.

the investigators will compare how two theta burst paradigms, intermittent theta burst stimulation (itbs) and continuous theta burst stimulation (ctbs), compare with sham tms in changing methamphetamine craving and brain activity. itbs, ctbs, and sham tms will be delivered in an accelerated fashion (two sessions daily, separated by 50 minutes). itbs will be delivered to the left dorsolateral prefrontal cortex (left dorsolateral prefrontal cortex), and ctbs will be delivered to the frontal pole. a brain mri scan will be done before and after the itbs/ctbs/sham tms sessions. the study involves four visits. each visit will last three hours. hence, participants will spend a total of 12 hours in the study.

Eligibility criteria:
inclusion criteria: * adults in the age group 18-65 years * able to read and understand english * able to provide informed consent * diagnosed with hiv * history of current or previous methamphetamine use disorder * endorse craving for methamphetamine * demonstrate an attentional bias for methamphetamine exclusion criteria: * traumatic brain injury * h/o seizure disorder * h/o or current diagnosis of schizophrenia * intracranial metal shrapnel * previous adverse effects with tms * sub-threshold consistency while performing behavioral tasks * lack of attentional bias to methamphetamine cues * a positive pregnancy test for female participants
effectiveness study of teacher training and social and financial education in rwanda's primary and secondary schools

Conditions: Active Learning Methods and Life-skills Education

Summary: the study uses experimental methods to evaluate the effectiveness of an educational intervention in rwanda. the intervention, designed by aflatoun and amir, involves training teachers on the use of active-learning methods to implement a social and financial education curriculum with students in primary and secondary schools. teachers then implement the social and financial curriculum with students in order to improve their personal, social, and financial competencies. teacher training will take place in november-december 2013 and the curriculum implementation will be evaluated in the 2014 school year. the study will examine the following hypotheses: 1. did teachers use of active learning methods in class increase due to the training received? 2. did students' levels of engagement and on-task behaviour increase as a result of the intervention's pedagogy and content? 3. did the following competencies of students improve due to the intervention? 1. self-efficacy 2. social skills 3. financial literacy 4. planning attitudes 5. savings attitudes 6. savings behavior 7. entrepreneurship 4. did the intervention change student's pass rates on the primary six (p6) and secondary three (s3) final examinations for the classes in which it was implemented? 5. did the intervention change student drop out rates in the classes which it was implemented?


Eligibility criteria:
inclusion criteria: * schools willing to participate in the intervention. * classes of students in grade p6 or s3 during academic year 2014 * teachers of entrepreneurship, social studies, or mathematics exclusion criteria: * non-consenting individuals

Keywords: teaching education active learning time on task financial education social education rights based education primary school life-skills
international validation of wearable sensor to monitor covid-19 like signs and symptoms

Conditions: COVID-19

Summary: 1. deploy wearable covid sensor to collect high resolution physiological data (temperature, cardiac, respiratory and physical activity) from covid positive patients. 2. use collected data to train algorithm for assessing the risk of individuals presenting with symptoms suggestive of covid-19.


Eligibility criteria:
inclusion criteria: * ages between 18-95 years old * currently experiencing any covid-like signs and symptoms such as fever, cough, shortness of breath, trouble breathing, persistent pain or pressure in the chest, confusion or inability to arouse, bluish lips or face. * individuals who are not experiencing any covid like signs and symptoms (will be asked to be healthy control) * able and willing to give written consent and comply with study procedures. exclusion criteria: * inability to understand instructions and follow a three step command. * the subject is pregnant, nursing or planning a pregnancy. * inability to provide written consent.

Keywords: wearable sensor machine learning covid-19
a clinical trial of cytotoxic t cells augmenting autologous hematopoietic stem cell (ahsc) transplantation for acute myeloid leukemia (aml)

Conditions: AML

Summary: the aim of this protocol is to investigate a novel form of immune therapy for patients with acute myelogenous leukemia (aml) who are in remission (cr) but who are at high risk for relapse.

primary aim: to conduct a phase 1/2 clinical trial of autologous ctl-mediated immunotherapy in a homogeneous group of patients with aml who have recently received an autologous hematopoietic stem cell transplant. specifically: phase 1: to determine the mtd of autologous aml-reactive cultured ctl in patients with aml who have recently received an ahsct. phase 2: to determine 1 year progression-free survival of the study group vs institutional historical control group composed of a sequential series of recent patients who have received an ahsct for aml.

Eligibility criteria:
inclusion criteria (initial eligibility screen): * diagnosis of aml, not m3 * at least 10% of circulating leukocytes are aml blast cells * age 18 through 75 * sex male or female * patient is considered a potential candidate for ahsct exclusion criteria (initial eligibility screen): * participation in another immunotherapy trial within 30 days * presence of active malignancy other than aml * history of autoimmune disease requiring systemic treatment * ecog performance status of 3 or 4 * major organ system dysfunction * recent (30 days) or current use of steroids other than topical skin preparations * history of allogeneic transplant * patients who, for any reason are not deemed candidates for ahsct eligibility for autologous ctl infusion: inclusion criteria: * patient has ctl that are in sufficient number and are suitable for infusion * patient is stable, afebrile, engrafted, ecog status 0-2, in cr and received ahsct 45 - 60 days earlier. exclusion or delay criteria: * temperature \> 38 c and/or known to be infected * absence of engraftment anc \> 500 and plt \> 20,000 unsupported * life expectancy less than 6 weeks * autoimmune disease requiring systemic treatment. * ecog performance status of 3 or 4 * major organ system dysfunction

Keywords: aml
prevention of very preterm delivery by testing for and treatment of bacterial vaginosis

Conditions: Pregnancy

Summary: background. anomalies of the vaginal flora (bacterial vaginosis, bv) are associated with an increased risk of late abortions and preterm birth. studies of antibiotic treatment of bv to reduce the risk of prematurity have not found a statistically significant diminution of risk (\<= 32 wks: or=0.49 \[0.05-5.1\], \< 37 wks: or=0.83 \[0.59-1.17\]).a partial explanation of these findings is that some of these treatment were administered vaginally, most often during the second or third trimester aim: to reduce the frequency of late abortions and very preterm birth by prescribing clindamycin vs placebo to patients diagnosed with bv before 13 weeks.

patients diagnosed with bv before 13 weeks will be divided into two groups. they will be defined as at low risk when they have no history of spontaneous preterm delivery or late abortion. women with such histories will be defined as at high risk. low risk patients will be asked to participate in a trial with 3 equal parallel groups, comparing two regimes of clindamycin (one or three 4-day treatments of clindamycin 300 mgx2/d) and placebo. high-risk patients will be asked to participate in a trial with 2 parallel groups to assess the usefulness of repeating antibiotic treatment monthly by comparing the administration of one 4-day treatment of clindamycin (300 mgx2/d) to three 4-day treatments, one month apart.

Eligibility criteria:
inclusion criteria: * nugent score \>= 7 * pregnant women \< 15 weeks (strictly) * signed informed consent * \>=18 old * speaking and understanding french language exclusion criteria: * metrorrhagias during 7 days before * birth anticipated in an other area * clindamycin allergy

Keywords: pregnancy preterm delivery bacterial vaginosis randomized clinical trial clindamycin
prayer in commbate to corona virus - covid -19

Conditions: Covid19

Summary: patients who are admitted to hospitalization in hcor and who have the confirmed diagnosis of corona virus, will be asked to consent to participate in this study that intends to study the effectiveness of the remote intercession prayer in combating this disease.

patients who agree to participate in the study will be separated into 2 groups, the intervention group and the control group. the identity of the patients will be kept in secret and only their initials will be listed. the intervention group will receive daily prayers and the evolutionary clinical results of the two groups will be purchased.

Eligibility criteria:
inclusion criteria: patients hospitalized in comun hospital rooms and intensive care units with confirmed covid-19. exclusion criteria: * patients admitted to the hcor emergency room, diagnosed with covid-19 infection, however, without indication for hospitalization * patients admitted to the hcor emergency room, diagnosed with covid-19 infection, however, without indication for hospitalization. * patients 18 years of age or older * patients with indication of palliative care and definition of terminality at hospital admission * patients who voluntarily choose not to participate in the study at the time of the • presentation of the informed consent form.
evaluation of safety of levocetirizine in routine clinical practice-non- interventional study

Conditions: Rhinitis Allergic, Persistent

Summary: to evaluate over a period of 6 months the safety and the treatment satisfaction of newly prescribed levocetirizine in patients of age ≥ 2 years with persistent allergic rhinitis.

this is a non-interventional, prospective, post-authorization, multi-centre cohort study in patients treated with levocetirizine. the baseline data will be collected at the visit to the physician when levocetirizine is prescribed for the first time for the patient for persistent allergic rhinitis. the data will then be collected during 2 visits occurring within the first 6 months of treatment, as usually scheduled in normal clinical practice in the czech and slovak republics. this is after approximately 4 weeks and 6 months of treatment or earlier, if the treatment is stopped

Eligibility criteria:
inclusion criteria: * diagnosis of persistent allergic rhinitis * first prescription of levocetirizine for this diagnosis for this patient * age ≥ 2 years exclusion criteria: * indications other than those defined in inclusion criteria * history of allergic or anaphylactic reactions to levocetirizine or other derivatives and excipients included

Keywords: levocetirizine xyzal rhinitis allergic persistent rhinitis nonseasonal
long-acting biomedical hiv prevention in transgender women

Conditions: HIV Prevention; Transgender Women

Summary: transgender women (tw) have unique challenges related to hiv prevention medication adherence. left unaddressed, these challenges will prevent tw from accessing the promising long-acting hiv prevention tools in the development pipeline. this study will develop a replicable process to tailor the delivery of these tools and an adherence intervention (that will include an mhealth app) to the needs of tw, using the example of inert injectable cabotegravir. work builds on a pilot study to identify tailored methods to deliver injectable cabotegravir in tw, such as self-injection and injection by a healthcare provider at at "drop-in" clinic. the investigators will use qualitative methods (e.g., interviews, group discussions called "design sessions") to design the adherence intervention and the mhealth app. then, investigators will execute a partially randomized patient-preference trial to determine if tw are able to use tailored injection strategies (self-injection or injection by a healthcare provider at "drop-in clinics") to improve adherence, compared to a control group of tw who will engage a protocol based on hptn-083/084. this will serve as a "proof of concept" for the future r01 that will test this on a larger scale. research and training will take place at nyspi/columbia, in affiliation with, 1) project affirm, a study of transgender identity (r01hd079603; pi: bockting), that will provide infrastructure for critical research activities (e.g., recruitment), and 2) slap-hiv, a clinical trial to produce a long-acting form of cabotegravir (e.g., injection; um1 ai120184; pi: hope). slap-hiv will provide clinical oversight (e.g., ensure tailored delivery strategies are feasible).


Eligibility criteria:
inclusion criteria: * hiv-negative * self-identified transgender woman (or woman assigned male at birth) * at least 18 years old * willing to complete injections * own a smartphone that uses apps * speak english or spanish * willing to take an hiv test * live in the nyc/tri-state area * report receptive or penetrative genital-to-genital sex with another person in the last 3 months exclusion criteria: * hiv-positive * does not identify as a transgender woman (or woman assigned male at birth) * younger than 18 * unwilling to complete injections * does not own a smartphone that uses apps * does not speak english or spanish * refuses hiv test * lives outside of the nyc/tri-state area * has not had receptive or penetrative genital-to-genital sex with another person in the last 3 months
an investigational study of experimental medication bms-986231 given in participants with different levels of liver function

Conditions: Liver Dysfunction; Liver Insufficiency; Hepatic Failure; Myocardial Failure; Cardiac Failure; Congestive Heart Failure; Heart Decompensation

Summary: this is an investigational study of experimental medication bms-986231 given to participants with weakened or damaged liver function.


Eligibility criteria:
for more information regarding bristol-myers squibb clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * body weight ≥ 45 kg and ≤ 120 kg and bmi ≥ 18 kg/m2 and ≤ 35 kg/m2 * heart rate ≥ 50 bpm and \< 95 bpm * women of childbearing potential must have a negative urine or serum pregnancy test (minimum sensitivity 25 iu/l or equivalent units of human chorionic gonadotropin \[hcg\]) within 24 hours prior to the start of study treatment exclusion criteria: * clinically relevant abnormal medical history, abnormal findings on physical examination, vital signs, ecg, or laboratory tests at screening that the investigator judges as likely to interfere with the objectives of the trial or the safety of the volunteer * history of chronic headaches (defined as occurring 15 days or more a month, over the previous 3 months), headaches related to caffeine withdrawal (ie, coffee, soda, tea, energy drinks, etc.), or moderately severe to severe headaches * history of migraine or cluster headaches other protocol defined inclusion/exclusion criteria could apply
clue: clinical utility study of esoguard

Conditions: Barrett Esophagus; Barretts Esophagus With Dysplasia; Esophagus Adenocarcinoma

Summary: utilize real-world data from the commercial use of esoguard testing on samples collected with esocheck (ec/eg) to evaluate the impact of esoguard results on health care provider's decision for endoscopy referral. assess patient compliance with recommendations for upper endoscopy, and relationship of compliance to positive esoguard results.


Eligibility criteria:
inclusion criteria: 1. individuals in whom the clinical decision has been made to screen for be using ec/eg 2. individuals who meet criteria for be screening in accordance with either the 2022 acg guidelines, or the aga best practice advice from their 2022 clinical practice update. exclusion criteria: 1. individuals who fall outside the eligible population defined by the esocheck device instructions for use (ifu) 2. individuals who do not meet either the acg or aga guidelines/practice advice for be screening 3. inability to provide written informed consent or participate in the required follow up